EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Reduced Mortality with Use of Point of Care Cell Suspension Autograft

Muzamil Ahmad iD, Soman Sen iD, Kathleen Romanowski iD, Tina Palmieri, David G Greenhalgh iD, Jason Heard iD

Journal of Burn Care & Research · 2025

DOI: 10.1093/jbcr/iraf221 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Burn Care & Research, 2025. Verfasst von Muzamil Ahmad und 5 weiteren Autor:innen. Beteiligte Einrichtung: Oakland University William Beaumont School of Medicine, Rochester, MI 48309, United States. Hauptthemen laut MEDLINE: Burns, Skin Transplantation. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cell suspension autograft (CSA) is a non-cultured, autologous cellular suspension used in partial-thickness burns or as an adjunct to widely meshed split-thickness skin grafts (STSGs). While CSA has been shown to improve patient outcomes in burn care, literature is limited in highlighting its impact on mortality when used in combination with STSG. This retrospective, matched, case–control study investigates the clinical efficacy of CSA in adult patients with burn injuries admitted to a regional burn center from 2015 to 2023. Patients treated with CSA and STSG (n = 63, “CSA-treated”) were compared against patients treated with STSG alone (n = 126, “non-CSA-treated”). Non-CSA-treated patients were matched in a 2:1 fashion to CSA-treated patients based on third-degree burned TBSA and age. Outcomes included mortality, length of stay (LOS), intensive care unit LOS (ICU LOS), and number of procedures. Multivariate analyses revealed that CSA-treated patients had a significant reduction in mortality (P = .0445) and a 78.9% reduction in odds of death (OR: 0.211) compared to non-CSA-treated patients. Cell suspension autograft-treated patients displayed nonsignificant increases in LOS (P = .0670), ICU LOS (P = .0851), and number of procedures (P = .9084). Selection and chronology bias may partially account for the improved mortality in the CSA-treated group. The nonsignificant increases in LOS, ICU LOS, and number of procedures may be reflective of increased survivorship. These findings demonstrate that CSA enhances survival in patients with burn injuries when used with STSG, warranting further research to confirm these results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BurnsSkin TransplantationHumansMaleFemaleRetrospective StudiesMiddle AgedCase-Control StudiesAdultTransplantation, AutologousAutograftsLength of Stay

Stichwörter der Autor:innen

burnscell suspension autograftmortalityskin transplantationtreatment outcome

Autor:innen und Institutionen

  • Oakland University William Beaumont School of Medicine, Rochester, MI 48309, United States.
  • Department of Surgery, University of California, Davis, Regional Burn Center, Davis, CA 95817, United States.
  • Shriners Hospital for Children Northern California, Sacramento, CA 95817, United States.

ORCID-Profile: Muzamil Ahmad, Soman Sen, Kathleen Romanowski, David G Greenhalgh, Jason Heard

Zitieren

APA

Ahmad, M., Sen, S., Romanowski, K., Palmieri, T., Greenhalgh, D. G., & Heard, J. (2025). Reduced Mortality with Use of Point of Care Cell Suspension Autograft. Journal of Burn Care & Research. https://doi.org/10.1093/jbcr/iraf221

Vancouver

Ahmad M, Sen S, Romanowski K, Palmieri T, Greenhalgh DG, Heard J. Reduced Mortality with Use of Point of Care Cell Suspension Autograft. Journal of Burn Care & Research. 2025. doi:10.1093/jbcr/iraf221

BibTeX
@article{Ahmad2025,
  author = {Ahmad, Muzamil and Sen, Soman and Romanowski, Kathleen and Palmieri, Tina and Greenhalgh, David G and Heard, Jason},
  title = {Reduced Mortality with Use of Point of Care Cell Suspension Autograft},
  journal = {Journal of Burn Care & Research},
  year = {2025},
  doi = {10.1093/jbcr/iraf221}
}
Kostenlos starten →